Sirana Pharma GmbH announces the appointment of Dr. Oliver von Stein as its new CEO. Dr. von Stein is a serial entrepreneur and brings a wealth of experience with over 20 years of C-level leadership experience in the Biopharma industry. He has led all aspects of corporate development including product approval, advancing drug candidates to phase III and growing companies to IPO listing. He has a proven business development track record, including major out-licensing deals with biotech and Pharma.
“Sirana Pharma has a unique and differentiated approach to the treatment of musculoskeletal disorders using its proprietary knowledge of micro-RNA targets. I am thrilled to be joining Sirana Pharma at this exciting time and to be part of such a talented and experienced leadership team. I look forward to the challenge of building the company and to strengthen Sirana Pharma’s position as a leader in miRNA targeting drugs.”